Marco Pravetoni

Marco Pravetoni

Auto-generated profile, based on publicly available information

Marco Pravetoni

Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2002 in Biology of Reproduction
Verified
Journal Article
Open access
PDF file
CRClaude Robert
Claude Robert
SMSerge McGraw
Serge McGraw
LMLyne Massicotte
Lyne Massicotte
MPMarco Pravetoni
Marco Pravetoni
Fulvio GandolfiFulvio Gandolfi
Fulvio Gandolfi
MSMarc Andre Sirard
Marc Andre Sirard
In mammals, the study of gene expression in the preimplantation embryo has been difficult because the standard procedures used to quantify mRNA gener

27 January 2017 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MMMaria Mavrikaki
Maria Mavrikaki
MPMarco Pravetoni
Marco Pravetoni
SPSarah Page
Sarah Page
DPDavid Potter
David Potter
ECElena Chartoff
Elena Chartoff

1 April 2012 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MPM. Pravetoni
M. Pravetoni
MNM. Le Naour
M. Le Naour
THT. M. Harmon
T. M. Harmon
ATA. M. Tucker
A. M. Tucker
PPP. S. Portoghese
P. S. Portoghese
PPP. R. Pentel
P. R. Pentel
Opioid conjugate vaccines have shown promise in attenuating the behavioral effects of heroin or morphine in animals. The goal of this study was to extend this approach to oxycodone (OXY), a commonly abused prescription opioid. Haptens were generated by adding tetraglycine (Gly)4 or hemisuccinate (HS) linkers at the 6-position of OXY. Immunization of rats with OXY(Gly)4 conjugated to the carrier proteins bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) produced high-titer antibodies to OXY and its metabolite oxymorphone with substantially lower affinities for other structurally related opioid agonists and antagonists. There was no measurable binding of antibody by the (Gly)4 linker alone or off-target opioids methadone and buprenorphine. OXY(HS) conjugates were less immunogenic despite achieving protein haptenation ratios comparable to OXY(Gly)4-BSA. In rats given a single intravenous dose of OXY, immunization with OXY(Gly)4-KLH increased OXY protein binding and retention in serum while decreasing its unbound (free) concentration in plasma and distribution to brain. Vaccine efficacy correlated with serum antibody titers, and it was greatest in rats given the lowest OXY dose (0.05 mg/kg) but was significant even after a larger OXY dose (0.5 mg/kg), equivalent to the high end of the therapeutic range in humans. These effects of OXY(Gly)4-KLH on drug disposition were comparable to those of nicotine or cocaine vaccines that are in clinical trials as addiction treatments. Immunization with OXY(Gly)4-KLH also reduced OXY analgesia in a thermal nociception test. These data support further study of vaccination with the OXY(Gly)4-KLH immunogen as a potential treatment option for OXY abuse or addiction.

1 November 2019 in Neuropharmacology
Verified
Journal Article
Closed access
MPMarco Pravetoni
Marco Pravetoni
SCSandra D. Comer
Sandra D. Comer

9 July 2008 in Genes, Brain and Behavior
Verified
Journal Article
Closed access
PDF file
MPM. Pravetoni
M. Pravetoni
KWK. Wickman
K. Wickman

1 June 2012 in Vaccine
Verified
Journal Article
Closed access
MPM. Pravetoni
M. Pravetoni
MRM D Raleigh
M D Raleigh
MNM. Le Naour
M. Le Naour
ATA.M. Tucker
A.M. Tucker
THT.M. Harmon
T.M. Harmon
PPP.R. Pentel
P.R. Pentel